Press Releases

Innovation and science concept

NEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES

Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables

Read More

Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials

Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection…

Read More

Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products

Bridgewater, NJ, OCTOBER 7, 2019 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.

Read More

Nevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products

Bridgewater, NJ, / Raleigh, NC, JUNE 18, 2019 – Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into a $50 million product financing agreement (the “Agreement”) with an affiliate of NovaQuest Capital Management, L.L.C. for the continued development of five differentiated, sterile injectable products.

Read More

Nevakar Completes $30 Million Financing to Advance Pipeline Products

Bridgewater, NJ, NOVEMBER 29, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple differentiated products in the ophthalmic and injectable areas, announced today that it has entered into a $20 million senior secured term loan with Oxford Finance LLC. As part of the financing agreement, Nevakar may also access an additional $10 million of funding provided that certain pre-defined milestone events are achieved. Proceeds from the financings will be used to accelerate the Company’s pipeline projects and for general corporate services.

Read More

Nevakar and Endo Enter into Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products

Bridgewater, NJ, AUGUST 8, 2018 – Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into an exclusive licensing agreement with Endo International plc’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the U.S. and Canada.

Read More

Nevakar featured in Tech News

Dr. Puri’s first venture, InnoPharma, was founded in 2005 with a focus on developing complex generic pharmaceuticals of sterile injectable dose forms. This was sold to Pfizer in 2014. Puri went on to found Nevakar, which is a specialty pharmaceutical company, focused on developing innovative products in injectable and ophthalmic space…

Read More

Nevakar Featured in Global Business Reports

InnoPharma’s acquisition was a strategic move by Pfizer; its product pipeline and track record of successfully developing and commercializing complex generic injectable products provided Pfizer a platform for further growth in this area. This was a great exit for InnoPharma’s shareholders as well as its team. After completing integration, I left Pfizer to found Nevakar in 2015.

Read More

Nevakar Announces $55 Million Fundraising / Press Release

BRIDGEWATER, NJ, July 27, 2016 – Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative products focused on therapies within the injectable and ophthalmic space, today announced that it has raised $55 million. Proceeds from the financing will be used to continue to develop the company’s product pipeline and for general corporate purposes. “Completion of this offering is a key milestone achievement for Nevakar, as it allows us to accelerate the development of our product pipeline to address significant unmet clinical and commercial needs,” said Navneet Puri, Ph.D., Founder and Chief Executive Officer of Nevakar. “Our product pipeline now contains multiple development programs that are expected to provide patient-centric benefits.”

Read More